Drugs / Allogeneic Myeloma Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01349569 | Jan 2012 → Oct 2016 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01045460 | Jan 2010 → Dec 2014 | plasma cell myeloma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Myeloma Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01349569 ↗ |
| Modality | Vaccine | “Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine” NCT01045460 ↗ |
| Route | Other | “five total intra-dermal injections” NCT01349569 ↗ |